Want to create an interactive transcript for this episode?
Podcast: OncLive® On Air
Episode: FDA Approval Insights: Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer
Description: Dr Matulonis discusses the FDA approval of mirvetuximab soravtansine-gynx in folate receptor alpha–positive, platinum-resistant ovarian cancer, key efficacy and safety data from the SORAYA trial, and how further research can continue the momentum behind finding effective ovarian cancer treatments.